daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT

Starting soon · Phase 3

Conditions studied: Transplant-Related Disorder

In brief

This study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.

Key facts

Study ID

NCT07588945

Run by

Institute of Hematology & Blood Diseases Hospital, China

People needed

438

Starts

2026-06-01

Expected to finish

2028-06-01

Last updated by the study team

2026-05-15

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 16 years old.
• HLA-haploidentical transplant.
• Able to take oral medications.
• Patients must provide written informed consent before the start of the study procedures.

You may not qualify if…

• Patients who have undergone tandem transplantation or multiple transplantations.
• Patients who are allergic to or cannot tolerate ruxolitinib.
• Patients with mental or other medical conditions that make them unable to comply with the study treatment and monitoring requirements.
• Patients who are ineligible for the study due to other factors, or who will bear great risk if they participate in the study.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.